Explore 3 Stock Ideas & Industry Insights Download Free Report

News

EnCore Energy Corp. (NASDAQ: EU) CEO Buys 10,000 Shares at $1.06

The transaction left Little Richard H with 60,000 shares, while the purchase represented about 16.7% of that resulting position.

Vinay Lochav | 22 September 2026

Brunswick Corp (NYSE: BC) Names Denari CEO at $1.15M Salary

Áine L. Denari will become chief executive officer on January 1, 2027, under employment terms that set her annual base salary at $1,150,000. David M. Foulkes will retire as chairman and chief executive officer on December 31, 2026.

Vinay Lochav | 22 September 2026

Greenbrier Companies (NYSE: GBX) Wins $600M Railcar Orders in Fourth Quarter

Greenbrier Companies received orders for 3,400 new railcars valued at approximately $600 million during its fiscal fourth quarter, including 780 units for Saudi Railway Company. The orders extend Greenbrier’s relationship with SAR and provide what management called a solid foundation entering fiscal 2027.Key HighlightsGreenbrier …

Vinay Lochav | 22 September 2026

MillerKnoll (NASDAQ: MLKN) Revises FY2027 Sales Guidance

MillerKnoll, Inc. (NASDAQ: MLKN) revised its fiscal 2027 net sales outlook. Adjusted diluted earnings per share guidance remained unchanged. The company also reported first-quarter results for the period ended August 29, 2026, including net sales of $923.4 million and adjusted diluted earnings per share …

Vinay Lochav | 22 September 2026

LIGAND PHARMACEUTICALS INC (NASDAQ: LGND) Buys Ryjunea Rights for $23M

$23 Million Purchase Covers Ryjunea Payment Rights

Vinay Lochav | 22 September 2026

Metagenomi Therapeutics (NASDAQ: MGX) Sets $120.7M Cash Runway Through Q4 2027

Metagenomi Therapeutics, Inc. (NASDAQ: MGX) is a Pharmaceuticals: Major company. Its September 2026 corporate presentation lists $120.7 million in cash at the end of Q2 2026 and anticipates that funding will support operations through Q4 2027. The company is advancing MGX-001 toward the clinic …

Vinay Lochav | 22 September 2026

PDS Biotechnology (NASDAQ: PDSB) Publishes Phase 2 Results Showing 39.3-Month Survival

PDS Biotechnology Corp. (NASDAQ: PDSB) is a Pharmaceuticals: Major company. Results from its VERSATILE-002 Phase 2 trial of PDS0101 with pembrolizumab showed median overall survival of 39.3 months in the overall CPS ≥1 population. PDS Biotech said it will prioritize PDS0301 in metastatic colorectal …

Vinay Lochav | 22 September 2026

PetVivo Holdings Adds Jaime K. Pickett to Board

Jaime K. Pickett became a director after Diane Levitan resigned, filling the vacancy while preserving the board’s existing size. Pickett brings experience in animal health, veterinary operations, corporate strategy,Businessdevelopment and medical technology commercialization.

Vinay Lochav | 22 September 2026

Tonix Pharmaceuticals (NASDAQ: TNXP) Expands TONMYA Coverage by 21M Medicare Lives

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a Pharmaceuticals: Major company, has added approximately 21 million Medicare Part D beneficiaries to TONMYA coverage through an agreement effective immediately.

Vinay Lochav | 22 September 2026
Support

Hi! How can we help you today?

Loading…